Review
Background
Materials and methods
Literature search
Data extraction and quality assessment
Inclusion and exclusion criteria
Subgroup analysis
Statistical analysis
Results
Study selection and characteristics
Reference | Date | Design | Jadad score | Treatment | Number of patients | Sex (M/F) | Mean age (years) | Tumor number (single/multiple) | Mean tumor size (cm) |
---|---|---|---|---|---|---|---|---|---|
Nishikawa | 2011 | NRCT | 1 | SR | 69 | 50/19 | 67.4 ± 9.7 | 69/0 | 2.68 ± 0.49 |
RFA | 162 | 95/67 | 68.4 ± 8.7 | 162/0 | 1.99 ± 0.62 | ||||
Tashiro | 2011 | NRCT | 1 | SR | 199 | 137/62 | 65.7 ± 9.0 | 132/67 | 2.1 ± 0.63 |
RFA | 87 | 53/34 | 66.3 ± 8.2 | 67/20 | 1.8 ± 0.52 | ||||
HUNG | 2011 | NRCT | 1 | SR | 229 | 184/45 | 60.07 ± 12.56 | 181/48 | 2.88 ± 1.06 |
RFA | 190 | 121/69 | 67.42 ± 11.45 | 152/38 | 2.37 ± 0.92 | ||||
Nanashima | 2010 | NRCT | 1 | SR | 144 | 112/32 | 63.6 ± 8.8 | 128/16 | NA |
RFA | 56 | 36/20 | 67.7 ± 8.5 | 51/5 | NA | ||||
Huang | 2010 | RCT | 4 | SR | 115 | 85/30 | 55.91 ± 12.68 | 89/26 | NA |
RFA | 115 | 79/36 | 56.57 ± 14.30 | 84/31 | NA | ||||
Ueno | 2009 | NRCT | 1 | SR | 123 | 82/41 | 67 (28 to 85) | 110/13 | 2.7 ± 0.1 |
RFA | 155 | 100/55 | 66 (40 to 79) | 101/54 | 2.0 ± 0.1 | ||||
Guglielmi | 2008 | NRCT | 1 | SR | 91 | 73/18 | NA | 69/22 | NA |
RFA | 109 | 88/21 | NA | 65/44 | NA | ||||
Hiraoka | 2008 | NRCT | 1 | SR | 59 | 44/15 | 62.4 ± 10.6 | NA | 22.7 ± 5.5 |
RFA | 105 | 76/29 | 69.4 ± 9.1 | NA | 19.8 ± 5.2 | ||||
Abu-Hilal | 2008 | NRCT | 3 | SR | 34 | 26/8 | 67 | NA | 3.8 (1.3 to 5) |
RFA | 34 | 27/7 | 65 | NA | 3 (2 to 5) | ||||
Takahashi | 2007 | NRCT | 1 | SR | 53 | 39/14 | 66 (41 to 80) | 41/12 | 2.5 (1 to 5) |
RFA | 171 | 120/51 | 69 (44 to 84) | 124/47 | 2.1 (0.7 to 4.8) | ||||
Chen | 2006 | RCT | 4 | SR | 90 | 75/15 | 49.4 ± 10.9 | NA | NA |
RFA | 71 | 56/15 | 51.9 ± 11.2 | NA | NA | ||||
Hong | 2005 | NRCT | 1 | SR | 93 | 69/24 | 49.2 ± 9.9 | NA | 2.5 ± 0.8 |
RFA | 55 | 41/14 | 59.1 ± 9.6 | NA | 2.4 ± 0.6 | ||||
Vivarell | 2004 | NRCT | 2 | SR | 79 | 57/22 | 65.2 ± 8.2 | 66/13 | NA |
RFA | 79 | 67/12 | 67.8 ± 8.7 | 46/33 | NA |
Meta-analysis results
Overall survival rates
Variables | Number of references with data | OR (95% CI) | Q test (P value) | I2(%) | Z test (P value) | Begg’s test (P value) | Egger’s test (P value) |
---|---|---|---|---|---|---|---|
Overall survival rates | |||||||
1 year | 0.60(0.42, 0.86) | 0.301 | 14.6 | 0.005 | 0.54 | 0.40 | |
3 years | 0.49(0.36, 0.65) | 0.036 | 45.8 | 0.000 | 0.2 | 0.15 | |
5 years | 0.60(0.43, 0.84) | 0.003 | 63.7 | 0.003 | 0.37 | 0.57 | |
Recurrence rates | |||||||
1 year | 1.48(1.05, 2.08) | 0.001 | 63.4 | 0.025 | 1.00 | 0.61 | |
3 years | 1.76(1.49, 2.08) | 0.000 | 69.9 | 0.000 | 0.20 | 0.15 | |
5 years | 1.68(1.21, 2.34) | 0.02 | 54.4 | 0.002 | 0.86 | 0.92 | |
Local recurrence | 0.34(0.09, 1.28) | 0.02 | 68.9 | 0.112 | NA | NA | |
Complications | 6.25(3.12, 12.52) | 0.042 | 54 | 0.000 | 1 | 0.982 |